Ebi Hiromichi

エビヒロミチ | Ebi Hiromichi

Affiliation and department：
Job title： Division Head
Other affiliations (1)：

Aichi Cancer Center, Research Institute

Research field (1)： Tumor diagnostics and therapeutics

Research theme for competitive and other funds (6)：

2020 - 2023 BRAF変異腫瘍の臓器多様性の解明とtumor agonistic治療への応用
2016 - 2019 Development of target therapy against KRAS mutant lung cancer stratified by EMT status.
2016 - 2019 Develop novel therapeutics against KRAS mutant cancer by regulating PI3K and ERK signal(Fostering Joint International Research)
2014 - 2016 Development of treatment strategy against KRAS mutant cancer by targeting PI3K and ERK
2012 - 2015 Study to overcome metastasis and targeted drug-resistance of lung cancer

Show all

Papers (75)：

Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, Keiji Hirata, Kozo Kataoka, Mitsuru Yokota, Kentaro Kato, Masahito Kotaka, Yoshinori Kagawa, Kun-Huei Yeh, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nature medicine. 2024. 30. 11. 3272-3283
Ryo Kimura, Yuta Adachi, Kentaro Hirade, Satoru Kisoda, Shogo Yanase, Noriko Shibata, Makoto Ishii, Yutaka Fujiwara, Rui Yamaguchi, Yasuko Fujita, et al. ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancers. 2024
Naoko Iida, Mitsuho Imai, Wataru Okamoto, Takeshi Kato, Taito Esaki, Ken Kato, Yoshito Komatsu, Satoshi Yuki, Toshiki Masuishi, Tomohiro Nishina, et al. Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. OF1-OF12
Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science. 2024. 115. 3. 1014-1021
Xianning Lai, Sarah Kit Leng Lui, Hiu Yan Lam, Yuta Adachi, Wen Jing Sim, Natali Vasilevski, Nicola J Armstrong, Stephanie Claire Bridgeman, Nathan Michael Main, Tuan Zea Tan, et al. SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition. NPJ precision oncology. 2023. 7. 1. 136-136

ｍore...

MISC (5)：

Kentaro Yamazaki, Satoshi Yuki, Hiroya Taniguchi, Hideaki Bando, Yu Sunakawa, Manabu Shiozawa, Hisateru Yasui, Naoki Takahashi, Hironaga Satake, Nobuhisa Matsuhashi, et al. Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC. ANNALS OF ONCOLOGY. 2022. 33. S479-S479
Hiromichi Ebi, Hideaki Bando. Precision oncology and the universal health coverage system in Japan. JCO Precision Oncology. 2019. 3
大坪公士郎, 足立雄太, 谷本梓, 西山明宏, 竹内伸司, 衣斐寛倫, 矢野聖二. 当科におけるFOLFIRINOX療法、GEM+nab-PTX療法導入後の膵癌化学療法の治療成績. 日本内科学会雑誌. 2017. 106. Suppl. 238-238
Development of drugs that overcome T790M-mutant EGFR in NSCLC. 2014. 13. 3. 376-383
Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, Takayuki Nakagawa, Shigeki Nanjo, Hiromichi Ebi, Takahiro Nakamura, Kunio Matsumoto, Manabu Soda, Hiroyuki Mano, et al. PARACRINE RECEPTOR LIGANDS ACTIVATE BYPASS TRACTS AND CAUSE ALK INHIBITOR RESISTANCE IN EML4-ALK LUNG CANCER CELLS. JOURNAL OF THORACIC ONCOLOGY. 2012. 7. 11. S455-S455

Professional career (1)：

MDPhD

Work history (8)：

2022/04 - 現在愛知県がんセンターゲノム医療センターセンター長
2018/04 - 現在 Aichi Cancer Center, Research Institute
2016/03 - 2018/01 Kanazawa University Cancer Research Institute
2012/06 - 2016/02 Kanazawa University Cancer Research Institute
2008/09 - 2012/05 マサチューセッツ総合病院がんセンター博士研究員

Show all

Awards (3)：

2021/09 - The Japanese Cancer Association JCA-Mauvernay Award
2015/09 - Japan Cancer Association Incitement Award
2007 - International Association for the Study of Lung Cancer Fellowship and Young Investigator Award

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page